加拿大结直肠癌游离DNA筛查的人群影响建模
cfDNA在高参与率下可检出更多结直肠癌病例并减少死亡,但成本更高;若参与率与FIT相同(43%),人群影响更差。
要点
- cfDNA筛查在高参与率下较FIT检出更多结直肠癌病例并减少死亡,但成本更高。
- cfDNA参与率需达约78%(80%依从)或69%(100%依从)才能使死亡低于结肠镜筛查水平。
- cfDNA参与率与FIT相同(43%)时,人群结局更差。
核心结论
- 该研究提示,若在人群层面实现高于既往研究报告的参与率,cfDNA筛查可能提高结直肠癌检出并降低死亡率。
研究设计与样本
- 比较每3年一次cfDNA筛查与结肠镜或粪便免疫化学检测(FIT)筛查。
主要发现
- 在较高参与率下,cfDNA在2024年至2092年间检出393 087例结直肠癌,而FIT情景检出156 009例。
- cfDNA较当前FIT预测减少121 383例死亡。
- 线性回归模型表明,cfDNA筛查需约78%参与率且80%依从,或69%参与率且100%依从,才能使死亡低于结肠镜筛查水平。
- cfDNA每获得一个健康调整人年成本为234.80加元(164.06美元),较FIT每多花费100 000加元(69 874美元)可避免0.025例死亡。
- 当cfDNA参与率与FIT相同(43%)时,人群总体影响更差(如死亡人数更多)。
临床怎么用
- 作者认为,患者对血液基与粪便基筛查接受度的意见可能有助于指导实际实施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cell-free DNA (cfDNA) testing is an emerging approach for colorectal cancer screening that has been approved in the US. The impact of cfDNA testing in the Canadian setting, assuming adherence mirroring prior real-world cfDNA work and assay performance from a Guardant Health study, is unknown. OBJECTIVE: To estimate how cfDNA screening impacts clinical and economic outcomes in Canada compared with existing screening approaches (fecal immunochemical testing [FIT] or colonoscopies). DESIGN, SETTING, AND PARTICIPANTS: The OncoSim-Colorectal model (version 3.6.5.7) was used to simulate participation, relative effectiveness, and cost of introduction of cfDNA tests every 3 years. A population of 32 million Canadians were simulated and examined for outcomes and costs between 2024 and 2092. EXPOSURES: Screening with colonoscopy, FIT, or cfDNA. MAIN OUTCOMES AND MEASURES: Screen-detected colorectal cancer cases, deaths, health-adjusted person-years, potential years of life lost, and cost of cancer screening and management were examined. RESULTS: Under higher participation, cfDNA detected 393 087 cases of colorectal cancer between 2024 and 2092 compared with 156 009 cases in the FIT scenario, and cfDNA reduced overall mortality by 121 383 deaths compared with current predictions with FIT. Linear regression models indicated that approximately 78% participation with 80% adherence or 69% participation with 100% adherence to cfDNA screening would be required to reduce deaths below the levels achieved by colonoscopy testing. Higher costs were associated with cfDNA testing, where each health-adjusted person-year had a cost of CAD $234.80 (US $164.06), and 0.025 deaths were averted per CAD $100 000 (US $69 874) additional dollars spent compared with FIT testing. When cfDNA testing was modeled with the same participation as FIT testing (43%), there was worse overall population impact (eg, greater number of deaths), emphasizing the importance of high participation for cfDNA testing to improve outcomes. CONCLUSIONS AND RELEVANCE: This study suggests that cfDNA testing could result in increased detection of colorectal cancer and reduced mortality if higher participation than reported in previous studies is achieved at the population level. Patient input on acceptance of blood-based vs stool-based screening may help inform real-world implementation.
引用
- Hutchinson JM, Ruan Y, Chia BJ, et al. Modeling Population-Level Impacts of Cell-Free DNA Screening for Colorectal Cancer in Canada. JAMA Oncol. 2025. PMID: 40310629. doi:10.1001/jamaoncol.2025.0908
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。